Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-21 | Dr. Gaurav D. ShahCEO & Director | -55,68k | 77,68k | Derivative Exercise and Sale | 1,69 - 3,09 | 1,47M | - |
| 2026-05-21 | Dr. Gaurav D. ShahCEO & Director | 20,81k | 35,18k | Derivative Exercise and Retained Stock | 1,69 | 1,47M | 1,44% |
| 2026-05-19 | Dr. Gaurav D. ShahCEO & Director | -2,41k | 7,26k | Verkauf | 3,01 | 1,45M | -0,17% |
| 2026-05-19 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -662,00 | 2,00k | Verkauf | 3,01 | 677,98k | -0,10% |
| 2026-05-19 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -384,00 | 1,16k | Verkauf | 3,01 | 89,78k | -0,43% |
| 2026-05-13 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -3,36k | 12,12k | Verkauf | 3,61 | 678,64k | -0,49% |
| 2026-05-13 | Dr. Gaurav D. ShahCEO & Director | -2,73k | 9,84k | Verkauf | 3,61 | 1,45M | -0,19% |
| 2026-05-13 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -855,00 | 3,08k | Verkauf | 3,61 | 90,16k | -0,94% |
| 2026-05-07 | Ms. Sarbani ChaudhuriChief Commercial & Medical Affairs Officer | -17,65k | 67,74k | Verkauf | 3,84 | 141,59k | -11,08% |
| 2026-02-18 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -1,16k | 3,86k | Verkauf | 3,34 | 91,02k | -1,26% |
| 2026-02-18 | Dr. Gaurav D. ShahCEO & Director | -5,99k | 19,99k | Verkauf | 3,34 | 1,45M | -0,41% |
| 2026-02-18 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -1,38k | 4,59k | Verkauf | 3,34 | 682,00k | -0,20% |
| 2026-02-13 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -12,25k | 40,58k | Verkauf | 3,31 | 121,56k | -9,16% |
| 2026-02-13 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -3,73k | 12,34k | Verkauf | 3,31 | 92,18k | -3,89% |
| 2026-02-13 | Dr. Gaurav D. ShahCEO & Director | -12,28k | 40,67k | Verkauf | 3,31 | 1,09M | -1,11% |
| 2026-01-02 | Dr. Elisabeth BjorkInsider | 10,00k | 34,40k | Kauf | 3,44 | 20,00k | 100,00% |
| 2025-11-18 | Dr. Jonathan SchwartzChief Science & Gene Therapy Officer | -2,55k | 7,59k | Verkauf | 2,98 | 127,19k | -1,96% |
| 2025-11-18 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -1,65k | 4,91k | Verkauf | 2,98 | 133,82k | -1,22% |
| 2025-11-18 | Dr. Gaurav D. ShahCEO & Director | -6,28k | 18,72k | Verkauf | 2,98 | 1,18M | -0,53% |
| 2025-11-18 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -1,09k | 3,24k | Verkauf | 2,98 | 65,92k | -1,62% |
| 2025-09-19 | RTW Investments, LPUnternehmen | -1,10M | 38,45M | Derivative Exercise and Sale | 3,11 - 40,03 | 18,19M | - |
| 2025-08-27 | Dr. Elisabeth BjorkInsider | 10,00k | 34,10k | Kauf | 3,41 | 10,00k | - |
| 2025-08-18 | Dr. Gaurav D. ShahCEO & Director | -2,23k | 6,81k | Sale to Issuer | 3,05 | 1,19M | -0,19% |
| 2025-08-18 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -1,59k | 4,84k | Verkauf | 3,00 - 3,07 | 135,46k | -1,16% |
| 2025-08-18 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -1,06k | 3,22k | Verkauf | 3,00 - 3,07 | 55,92k | -1,86% |
| 2025-08-18 | Dr. Jonathan SchwartzChief Science & Gene Therapy Officer | -2,49k | 7,56k | Verkauf | 3,00 - 3,07 | 124,66k | -1,95% |
| 2025-08-14 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -12,11k | 36,56k | Verkauf | 3,02 | 137,05k | -8,12% |
| 2025-08-14 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -7,04k | 21,26k | Verkauf | 3,02 | 56,98k | -11,00% |
| 2025-08-14 | Dr. Jonathan SchwartzChief Science & Gene Therapy Officer | -11,16k | 33,70k | Verkauf | 3,02 | 124,23k | -8,24% |
| 2025-07-03 | Mr. Aaron OndreyInsider | -1,48k | 4,26k | Verkauf | 2,88 | 10,53k | -12,31% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
